BioLineRx Ltd. (BLRX) Income Statement
BLRX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBLRX revenue and net income
Where BLRX's revenue goes
2025Each bar shows an amount and its share of revenue. BLRX kept −99.6% of revenue as net income.
BLRX profit margins
BLRX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −95.9% | — | — | — |
| Gross profit | −97.8% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BLRX quarterly EPS vs estimates
BioLineRx beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 23, 2026 (estimate $-0.38).
BLRX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $28.9M | $4.8M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $758,973 | $9.3M | $3.7M | $654,000 | $702,000 | $934,000 | $940,000 | $451,000 | $480,675 | $481,888 |
| Gross profit | $430,387 | $19.7M | $1.1M | −$654,000 | −$702,000 | −$934,000 | −$940,000 | −$451,000 | −$480,675 | −$481,888 |
| Research & development | $7.7M | $9.1M | $12.5M | $17.6M | $19.5M | $18.2M | $23.4M | $19.8M | $19.5M | $11.2M |
| Sales, general & admin | $3.9M | $28.5M | $31.2M | $11.5M | $5.3M | $4.7M | $4.6M | $5.8M | $5.7M | $5.3M |
| Total operating expenses | $10.8M | $40.1M | $50.8M | $29.2M | $24.8M | $22.9M | $28.1M | $25.6M | $25.2M | $16.5M |
| Operating income | −$10.4M | −$20.4M | −$49.7M | −$29.2M | −$24.8M | −$22.9M | −$28.1M | −$25.6M | −$25.2M | −$16.5M |
| Interest income | $1.1M | $1.8M | $2.0M | $694,000 | $559,000 | $236,000 | $777,000 | $719,000 | $824,000 | $480,000 |
| Interest expense | $1.3M | $9.2M | $2.2M | $2.2M | $984,000 | $1.5M | $1.8M | $21,000 | $21,000 | $14,000 |
| Income before taxes | −$2.0M | −$9.2M | −$60.6M | −$25.0M | −$27.1M | −$30.0M | −$25.4M | −$23.0M | −$24.4M | −$15.8M |
| Income taxes | — | — | $1,000 | −$4.2M | $1.1M | $911,000 | $1.4M | $2.7M | −$239,000 | −$665,000 |
| Net income | −$1.2M | −$9.2M | −$60.6M | −$25.0M | −$27.1M | −$30.0M | −$25.4M | −$23.0M | −$24.4M | −$15.8M |
| EBITDA | −$224,770 | $3.9M | −$57.1M | −$22.1M | −$25.4M | −$27.6M | −$22.7M | −$21.9M | −$24.8M | −$16.0M |
| EPS (diluted) | −$3.07 | −$0.08 | −$30.15 | −$12.49 | −$12.90 | −$78.00 | −$56.10 | −$102.60 | −$115.20 | −$132.96 |
| Gross margin | 36.2% | 68.0% | 23.1% | — | — | — | — | — | — | — |
| Operating margin | −871.8% | −70.5% | −1,035.3% | — | — | — | — | — | — | — |
| Net margin | −99.6% | −31.9% | −1,262.8% | — | — | — | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $299,048 | $477,000 | $195,211 | $427,000 | $304,000 | $255,000 | $11.7M | $4.9M | $5.4M | $6.9M | $4.8M | $0 |
| Cost of revenue | $139,352 | $95,000 | $103,643 | $84,000 | $72,000 | $34,000 | $6.1M | $822,000 | $897,000 | $1.5M | $3.7M | $221,000 |
| Gross profit | $159,695 | $382,000 | $91,568 | $343,000 | $232,000 | $221,000 | $5.7M | $4.1M | $4.5M | $5.4M | $4.8M | −$221,000 |
| Research & development | $3.0M | $2.5M | $2.4M | $1.7M | $2.3M | $1.6M | $1.9M | $2.6M | $2.2M | $2.5M | $3.1M | $2.7M |
| Sales, general & admin | $865,000 | $858,000 | $831,000 | $831,000 | $209,000 | $989,000 | $14.1M | $6.9M | $8.0M | $7.7M | $15.6M | $9.6M |
| Total operating expenses | $3.8M | $3.4M | $3.5M | $2.5M | $2.5M | $2.6M | $10.1M | $9.5M | $10.3M | $10.2M | $23.4M | $12.4M |
| Operating income | −$3.6M | −$3.0M | −$3.4M | −$2.2M | −$2.3M | −$2.4M | −$4.4M | −$5.4M | −$5.8M | −$4.8M | −$18.6M | −$12.4M |
| Interest income | $132,000 | $208,000 | $37,000 | $377,000 | $490,000 | $294,000 | $286,000 | $434,000 | $535,000 | $565,000 | $718,000 | $312,000 |
| Interest expense | $211,571 | $250,000 | $281,749 | $304,000 | $276,000 | $420,000 | $4.4M | $1.6M | $2.1M | $929,000 | $932,000 | $837,000 |
| Income before taxes | −$4.4M | −$2.6M | −$2.2M | −$977,000 | −$3.9M | $5.1M | −$3.2M | −$5.8M | $484,000 | −$696,000 | −$13.9M | −$16.0M |
| Income taxes | — | — | — | — | — | — | — | — | — | $5.4M | −$4.6M | −$2.3M |
| Net income | −$3.1M | −$2.6M | −$1.4M | −$977,000 | −$3.9M | $5.1M | −$3.2M | −$5.8M | $484,000 | −$696,000 | −$13.9M | −$16.0M |
| EBITDA | −$3.6M | −$2.2M | −$1.9M | −$554,000 | −$3.5M | $5.7M | $3.1M | −$3.4M | $3.0M | $1.1M | −$14.1M | −$15.0M |
| EPS (diluted) | −$0.77 | −$0.58 | −$0.32 | −$0.23 | −$1.02 | −$1.50 | $0.00 | −$0.07 | $0.01 | −$0.01 | −$0.15 | −$12.00 |
| Gross margin | 53.4% | 80.1% | 46.9% | 80.3% | 76.3% | 86.7% | 48.2% | 83.4% | 83.4% | 78.8% | 100.0% | — |
| Operating margin | −1,215.3% | −629.8% | −1,745.4% | −516.9% | −757.6% | −937.6% | −37.7% | −109.0% | −107.0% | −70.3% | −386.8% | — |
| Net margin | −1,029.3% | −541.1% | −713.9% | −228.8% | −1,296.1% | 2,010.6% | −27.1% | −117.8% | 9.0% | −10.2% | −289.2% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BLRX's financial statements (latest annual report filed March 23, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BLRX financial results
In fiscal year 2025 (ended December 31, 2025), BioLineRx reported revenue of $1.2 million, down 95.9% from the year before. It had a net loss of $1.2 million, a net profit margin of −99.6%. Diluted earnings per share came to −$3.07.
See the BLRX stock overview for the latest quote and news, or the BLRX chart for price history and technical indicators.
BLRX income statement FAQ
What is BioLineRx's annual revenue?
BioLineRx reported total revenue of $1.2 million for fiscal year 2025, which ended on December 31, 2025. That was down 95.9% from $28.9 million the previous year.
Is BioLineRx profitable?
No. BioLineRx reported a net loss of $1.2 million in fiscal 2025, a net profit margin of −99.6%; its operating margin was −871.8%.
What is BioLineRx's gross margin?
BioLineRx's gross margin was 36.2% in fiscal 2025: for every $100 of revenue, BioLineRx kept $36 after the direct cost of its products and services.
How much does BioLineRx spend on research and development?
BioLineRx spent $7.7 million on research and development in fiscal 2025, 643.9% of revenue.
What are BioLineRx's earnings per share?
BioLineRx earned $-3.07 per diluted share in fiscal 2025, compared with $-0.08 a year earlier.
When will BioLineRx report its next earnings?
BioLineRx is expected to report results for the quarter ending September 30, 2026 on November 23, 2026 before the market opens.
When does BioLineRx's fiscal year end?
BioLineRx's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 23, 2026.